Camlin Fine Sciences Limited has announced a crucial board meeting scheduled for September 29, 2025, to deliberate on a significant strategic move. The company is set to consider issuing equity shares through preferential allotment as part of a share swap arrangement, aiming to acquire a majority stake in Vinpai S.A.

Key Highlights

• Board Meeting Date: September 29, 2025
• Purpose: To consider and potentially approve the issuance of equity shares via preferential allotment
• Acquisition Target: Majority stake in Vinpai S.A.
• Method: Share swap arrangement
• Approval Process: Subject to shareholder approval through postal ballot

Trading Window Closure

In compliance with regulatory requirements, Camlin Fine Sciences has implemented a trading window closure:

• Closure Period: September 24, 2025, until 48 hours after the board meeting concludes
• Applicable to: Insiders, designated persons, and their immediate relatives

Background and Regulatory Compliance

The upcoming board meeting is a continuation of Camlin Fine Sciences' strategic plans, following previous disclosures made in February and June 2025 regarding the Vinpai acquisition. The company has emphasized that the proposed preferential issue for the share swap will be conducted in accordance with:

• The Companies Act, 2013, and its associated rules
• Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018
• Other applicable laws and regulatory approvals

Shareholder Approval Process

If the board approves the proposal, Camlin Fine Sciences intends to initiate a postal ballot process to seek shareholder approval for the preferential issue related to the share swap. This step underscores the company's commitment to transparent corporate governance and shareholder engagement in major strategic decisions.

Market Implications

The proposed acquisition of a majority stake in Vinpai S.A. through a share swap arrangement could potentially strengthen Camlin Fine Sciences' market position and expand its operational capabilities. Investors and market analysts will be closely watching the outcome of the September 29 board meeting and the subsequent shareholder approval process.

Stakeholders are advised to stay tuned for further updates and official announcements from the company regarding the progress of the Vinpai acquisition and its potential impact on Camlin Fine Sciences' future growth trajectory.

Camlin Fine Sciences , a leading specialty chemicals manufacturer, reported a narrowed consolidated net loss for the first quarter, despite a slight dip in revenue. The company's financial results, released on August 8, show signs of improvement in its continuing operations while grappling with challenges in certain business segments.

Financial Highlights

The company reported a consolidated net loss of 100.00 million rupees for Q1, significantly lower than the 340.00 million rupee loss in the same period last year. This improvement came despite a marginal decrease in revenue, which stood at 4,236.00 million rupees compared to 4,375.00 million rupees in the previous quarter.

Revenue and Segment Performance

Camlin Fine Sciences saw mixed performance across its business segments:

• Specialty Ingredients (Straights): Revenue decreased to 806.00 million rupees from 976.00 million rupees in the previous quarter, reflecting sluggish demand.
• Specialty Ingredients (Value-added Blends): This segment showed strong growth, with revenue increasing to 2,327.00 million rupees from 1,949.00 million rupees in the previous quarter.
• Performance Chemicals: Revenue declined to 473.00 million rupees from 586.00 million rupees in the previous quarter.
• Aroma Ingredients: This segment remained relatively stable with a slight decrease to 564.00 million rupees from 608.00 million rupees in the previous quarter.

Profitability and Margins

The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for Q1 stood at 190.00 million rupees, down from 594.00 million rupees in the previous quarter. Consequently, the EBITDA margin contracted to 4.49% from 13.58% in the previous quarter.

Regional Performance

Management Commentary

Ashish S. Dandekar, Chairman & Managing Director of Camlin Fine Sciences, stated, "While we faced challenges in our Specialty Ingredients Straights business due to sluggish demand, our Blends business continues to witness strong growth in key markets. The Vanillin business remained stable despite channel stocks and tariff uncertainty."

Outlook

The company continues to focus on its core strengths in specialty chemicals, with a particular emphasis on high-value blends and additives. Camlin Fine Sciences is also working on developing new downstream products and enhancing its product portfolio in naturals and emulsifiers.

Corporate Developments

The Board of Directors approved the re-appointment of Mr. Joseph Conrad D'Souza as a Non-Executive Independent Director for a second term of five years, subject to shareholder approval. Additionally, Mr. Hari Rajmohan was appointed as an Alternate Director to Mr. Jens Van Nieuwenborgh during the latter's absence.

In conclusion, while Camlin Fine Sciences faces some headwinds in certain segments, the company's efforts in reducing losses and growing its value-added blends business indicate a strategic focus on improving overall performance in the coming quarters.